CSTONE PHARMA-B (02616) has announced its intention to repurchase up to 136 million shares on the open market from time to time. This plan is authorized under the general mandate for share repurchases approved by shareholders at the company's annual general meeting held on June 25, 2025, and any subsequent general mandates approved at future general meetings.

The company's core product, CS2009 (a PD-1/VEGF/CTLA-4 trispecific antibody), is set to have its latest clinical data presented at the upcoming ASCO Annual Meeting. The timely implementation of this share repurchase plan demonstrates the strong confidence of the company's management and board in its research and development achievements, commercialization progress, and long-term business development. It also reflects the company's commitment to enhancing shareholder value and continuously improving its capital return mechanisms.